<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">

De-Risking the Unknown: Optimizing Statistical Design for Clinical Strategy 

Thursday, April 29, 2021 

8 AM PDT | 11 AM EDT | 5 PM CET

Statisticians remain an overlooked asset in the development of sound clinical strategy.

In the webinar Dr. Jemiai will not only answer the below questions, but share a solution for achieving clinical trial success.

  • What if statisticians could enter a Governance Board meeting, with hundreds of potential clinical trial designs that reflect various targets of trial speed, trial cost and trial success?
  • What if statisticians could adjust and update designs in real time, as new desirables are revealed, showing executives how a clinical trial could be de-risked?

Join Dr. Yannis Jemiai, Cytel’s Chief Scientific Officer, who will discuss Solara, a collaborative decision-support platform that gives statisticians the ability to run tens of millions of simulations within minutes and communicate the benefits of various designs using graphics and other non-technical communication methods.

With Solara statisticians can quickly illuminate tradeoffs in speed, savings and success of a clinical trial, showing Governance Boards how to quickly choose a trial beneficial for their needs. As questions arise designs can be refined in real time, saving statisticians hundreds of hours in trial design time, and providing more rigorously justified design options from which a Governance Board can choose.

Register today!

Please provide your details to register

Meet the Speaker: Dr. Yannis Jemiai

600w_Yannis-Jemiai,-Chief-Scientific-Officer,-Cytel
                                                                                                                                                                       
Dr. Yannis Jemiai is the Chief Scientific Officer at Cytel. A biostatistician by training, who has written numerous articles on decision rules, Go/No-Go decision-making, and other ways to quantify commercial strategy using insights from clinical trial design.